The relationship between the responses to prior systemic therapies and the efficacy of subsequent pemetrexed (Pem) therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Sun, J. [1 ,2 ]
Oh, D. [1 ,2 ]
Lee, S. [1 ,2 ]
Kim, D. [1 ,2 ]
Im, S. [1 ,2 ]
Kim, T. [1 ,2 ]
Lee, J. [1 ,2 ]
Kim, Y. [1 ,2 ]
Heo, D. S. [1 ,2 ]
Bang, Y. [1 ,2 ]
机构：
[1] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[2] Seoul Natl Univ Hosp, Bundang Hosp, Seoul 110744, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8061
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer
    Sun, Jong-Mu
    Oh, Do-Youn
    Lee, Se-Hoon
    Kim, Dong-Wan
    Im, Seock-Ah
    Kim, Tae-You
    Lee, Jong Seok
    Kim, Young-Whan
    Heo, Dae Seog
    Bang, Yung-Jue
    LUNG CANCER, 2010, 68 (03) : 427 - 432
  • [2] Expression of folate pathway regulators and pemetrexed (pem) activity in patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Gianoncelli, Letizia
    Toschi, Luca
    Canal, Barbara
    Lo Russo, Chiara
    Rubino, Luca
    Finocchiaro, Giovanna
    Giordano, Laura
    Destro, Annarita
    Garassino, Isabella M. G.
    Cavina, Raffaele
    Siracusano, Licia
    Roncalli, Massimo
    Carbone, Antonino
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] PEMETREXED (PEM) COMBINATION THERAPY WITH CARBOPLATIN (CB) FOLLOWED BY PEM MAINTENANCE IN JAPANESE PATIENTS (PTS) WITH NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): SUBGROUP ANALYSIS OF ELDERLY PTS
    Nogami, N.
    Sekiguchi, R.
    Enatsu, S.
    Nakagawa, K.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2012, 23 : 393 - 394
  • [4] Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
    Subramanian, J.
    Moreno, V.
    Bosch-Barrera, J.
    Pikiel, J.
    Kristeleit, R.
    Guo, W.
    Danaee, H.
    Im, E.
    Roda, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S887
  • [5] Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion plus non-small cell lung cancer (NSCLC)
    Gautschi, O.
    Drilon, A.
    Tan, D. S. W.
    Oxnard, G. R.
    McCoach, C.
    Goto, K.
    Park, K.
    Alonso Casal, G.
    de Braud, F.
    French, P.
    Soldatenkova, V.
    Besse, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S835 - S835
  • [6] Phase I/II study of MKC-1 and pemetrexed (PEM) as second-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Hanna, N. H.
    Estes, D.
    Arnott, J.
    Marcotte, S.
    Hannah, A.
    Sidor, C. F.
    West, H.
    Clamon, G.
    Hoang, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Phase II study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC).
    Schmid-Bindert, Gerald
    Gebbia, Vittorio
    Mayer, Frank
    Arriola, Edurne
    Marquez-Medina, Diego
    Syrigos, Konstantinos N.
    Biesma, Bonne
    Leschinger, Monika Iris
    Grul, Carla M. Visseren
    Frimodt-Moller, Bente
    Ripoche, Veronique
    Myrand, Scott
    Tuan Nguyen
    Zimmermann, Annamaria
    Schuette, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Randomized phase II study of pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) versus pem alone in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Li, Tianhong
    Piperdi, Bilal
    Walsh, William Vincent
    Kim, Mimi
    Gucalp, Rasim
    Haigentz, Missak
    Bathini, Venu Gopal
    Wu, Xiaoxia
    Pasquinelli, Patricia
    Gajavelli, Srikanth
    Sreedhara, Meera
    Beckett, Laurel A.
    Lara, Primo
    Gandara, David R.
    Perez-Soler, Roman
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] A phase I study of enzastaurin (Enz) combined with pemetrexed (Pem) in advanced non-small cell lung cancer (NSCLC)
    Takahashi, T.
    Yamamoto, N.
    Murakami, H.
    Ohe, Y.
    Kunitoh, H.
    Nokihara, H.
    Koshiji, M.
    Tamura, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] A large retrospective analysis of the activity of pemetrexed (PEM) in patients (pts) with ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC) prior to crizotinib (CRIZ)
    Scagliotti, Giorgio
    Kim, Dong-Wan
    Shaw, Alice Tsang
    Ou, Sai-Hong Ignatius
    Riely, Gregory J.
    Gettinger, Scott N.
    Besse, Benjamin
    Thomas, Michael
    Salgia, Ravi
    Wilner, Keith D.
    Bartlett, Cynthia Huang
    Polli, Anna
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345